In the past, survival in Multiple Myeloma was in the range of 1 to 3 years. With the introduction of the novel drugs as the immunomodulators (IMiDs) and Proteosome inhibitors, survival has markedly increased and quality of life has improved. In this book, I have given an overview of the novel drugs and their use as first line therapy in multiple myeloma aiming for better prognosis, survival and quality of life.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
In the past, survival in Multiple Myeloma was in the range of 1 to 3 years. With the introduction of the novel drugs as the immunomodulators (IMiDs) and Proteosome inhibitors, survival has markedly increased and quality of life has improved. In this book, I have given an overview of the novel drugs and their use as first line therapy in multiple myeloma aiming for better prognosis, survival and quality of life.
Oncology Specialist, Assistant Lecturer of Medical Oncology, National Cancer Institite, Cairo University, Egypt. Clinical Fellow of Hemato-oncology, Princess Margaret Hospital, Toronto, Canada. Master Degree student in Advanced Oncology, Ulm University, Germany.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -In the past, survival in Multiple Myeloma was in the range of 1 to 3 years. With the introduction of the novel drugs as the immunomodulators (IMiDs) and Proteosome inhibitors, survival has markedly increased and quality of life has improved. In this book, I have given an overview of the novel drugs and their use as first line therapy in multiple myeloma aiming for better prognosis, survival and quality of life. 140 pp. Englisch. N° de réf. du vendeur 9783846557945
Quantité disponible : 2 disponible(s)
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. N° de réf. du vendeur 26394694170
Quantité disponible : 4 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Rabea AhmedOncology Specialist, Assistant Lecturer of Medical Oncology, National Cancer Institite, Cairo University, Egypt. Clinical Fellow of Hemato-oncology, Princess Margaret Hospital, Toronto, Canada. Master Degree student in Adv. N° de réf. du vendeur 5498944
Quantité disponible : Plus de 20 disponibles
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand. N° de réf. du vendeur 401682885
Quantité disponible : 4 disponible(s)
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. PRINT ON DEMAND. N° de réf. du vendeur 18394694160
Quantité disponible : 4 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -In the past, survival in Multiple Myeloma was in the range of 1 to 3 years. With the introduction of the novel drugs as the immunomodulators (IMiDs) and Proteosome inhibitors, survival has markedly increased and quality of life has improved. In this book, I have given an overview of the novel drugs and their use as first line therapy in multiple myeloma aiming for better prognosis, survival and quality of life.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 140 pp. Englisch. N° de réf. du vendeur 9783846557945
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - In the past, survival in Multiple Myeloma was in the range of 1 to 3 years. With the introduction of the novel drugs as the immunomodulators (IMiDs) and Proteosome inhibitors, survival has markedly increased and quality of life has improved. In this book, I have given an overview of the novel drugs and their use as first line therapy in multiple myeloma aiming for better prognosis, survival and quality of life. N° de réf. du vendeur 9783846557945
Quantité disponible : 1 disponible(s)
Vendeur : preigu, Osnabrück, Allemagne
Taschenbuch. Etat : Neu. First line therapy in Multiple Myeloma | Overview of recent therapy in treatment of new Multiple Myeloma patients | Ahmed Rabea | Taschenbuch | 140 S. | Englisch | 2011 | LAP LAMBERT Academic Publishing | EAN 9783846557945 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu. N° de réf. du vendeur 106721451
Quantité disponible : 5 disponible(s)
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. 140 pages. 8.66x5.91x0.32 inches. In Stock. N° de réf. du vendeur __3846557943
Quantité disponible : 1 disponible(s)
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. 140 pages. 8.66x5.91x0.32 inches. In Stock. N° de réf. du vendeur 3846557943
Quantité disponible : 1 disponible(s)